Alstonine Composition Inhibiting IL-17 and IL-12/23 Cytokines
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cytokine therapies for skin-related disorders, such as psoriasis and eczema, often result in adverse side effects and are expensive, with oral administration being unsuitable for all patients, and there is a need for a novel topical composition that can modulate cytokines like IL 17 and IL 12/23 without harm.
Innovation Solution
A pharmaceutical composition comprising alstonine, along with other active ingredients like DM Water, Glycerine, Cetyl palmitate, Shea butter, and Dimethicone, is developed to inhibit IL 17 and IL 12/23 activity, suitable for both topical and oral use, providing a safer and more effective treatment for skin-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If anti-cytokine therapy is used to treat skin-related disorders, then inflammation is reduced, but side effects such as latent microbial infection, demyelinating, secondary autoimmune manifestation, and thromboembolism occur
Solution Approach 1:
The patent extracts and isolates alstonine as a specific active compound from natural sources, focusing on targeting particular cytokines (IL-17 and IL-12/23) rather than using broad-spectrum anti-cytokine therapies. This selective extraction approach aims to reduce inflammation while minimizing off-target side effects associated with conventional therapies.
Solution Approach 2:
Alstonine acts as an intermediary substance that modulates cytokine activity indirectly rather than completely blocking cytokine pathways. This intermediate modulation approach may provide therapeutic benefit while avoiding the extreme side effects associated with complete cytokine inhibition.
2Ease of operation
If oral route is used for drug administration, then treatment is convenient, but absorption is very slow and unsuitable for uncooperative patients
Solution Approach 1:
The patent provides the composition in multiple dosage forms (topical cream and oral tablet) segmented for different administration needs. The topical cream offers rapid local action for skin conditions, while tablets provide systematic delivery for broader therapeutic effects, allowing patients to choose based on their specific needs and cooperation level.
Solution Approach 2:
The pharmaceutical composition is designed with multi-functionality, capable of being administered through both topical and oral routes depending on patient requirements. This universal approach ensures the same active compound can serve different therapeutic purposes and accommodate different patient populations including uncooperative patients.
3Reliability
If conventional anti-cytokine therapy is used, then treatment effectiveness is achieved, but cost is expensive and not affordable for every patient
Solution Approach 1:
The patent utilizes alstonine, a naturally occurring compound that can be produced through plant cultivation and extraction, potentially offering a more cost-effective alternative to expensive synthetic biologics. The natural source material and relatively simple extraction process may reduce manufacturing costs while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent changes the chemical parameter by using a small molecule alkaloid (alstonine) instead of large protein-based biologics. This parameter change from biologic to small molecule therapy typically results in lower manufacturing costs, improved stability, and reduced treatment expense while maintaining efficacy.
Data Source
AI summary
The present invention relates to interleukins (IL 17 and IL12/23) activity inhibiting composition. Further the present invention is related to novel compositions comprising active pharmaceutical ingredient, optionally in combination with other active pharmaceutical ingredients which are capable of treating the skin diseases or disorders and inhibiting the interleukins (IL 17 and IL12/23) activity. The present invention composition Alstonine compound, an emulsifier, an opacifier, a lubricant, a non-ionic surfactant and excipients including demineralized water.